Send to

Choose Destination
Dev Med Child Neurol. 2016 Nov;58(11):1193-1199. doi: 10.1111/dmcn.13167. Epub 2016 Jun 8.

Use of modified Atkins diet in glucose transporter type 1 deficiency syndrome.

Author information

Service de Neurologie Pédiatrique, AP-HP, Hôpital Robert Debré, Paris, France.
Service de Explorations Fonctionnelles, AP-HP, Hôpital Robert Debré, Paris, France.
Service de Neurologie Pédiatrique, AP-HP, Hôpital Robert Debré, Paris, France.
INSERM U1141, Paris, France.
Sorbonne Paris Cité, INSERM UMR1141, Université Paris Diderot, Paris, France.



Glucose transporter type 1 deficiency syndrome (GLUT1-DS) results from impaired glucose transport into the brain, and is treated with a ketogenic diet. A few reports have suggested effectiveness of treatment using the modified Atkins diet (MAD). We aimed to assess the efficacy of MAD as a treatment for GLUT1-DS.


We evaluated the efficacy of MAD in 10 patients (four males, six females; mean age at diagnosis [SD] 6.2y [1.7], min-max: 4mo-12y) with GLUT1-DS.


MAD was started at diagnosis in eight patients, including two infants. The mean duration (SD) under MAD was 2.5 [0.6] years (range 6mo-6y). Seven patients with epilepsy started MAD at GLUT1-DS diagnosis, and all experienced improvements in their epilepsy: five out of seven were seizure-free at M1, and three out of six at M3 and M6. The initiation of MAD allowed symptoms to be controlled in the three patients with movement disorders but without seizures. Two patients switched from the ketogenic diet to MAD. This switch was not responsible for the recurrence of any symptoms, and led to improvements in both physical abilities and growth parameters.


MAD, which is a less restrictive and more palatable diet than the ketogenic diet, seems to have comparable effectiveness. Moreover, a switch from the ketogenic diet to MAD appears to be beneficial for patients with GLUT1-DS.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center